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J.A.,
a 6 y e a r -o l d g i r l with small g o i t r e had e l e v a t e d l e v e l s o f T4, T 3 a s well cis TSH. Her high and w e i e h t were a t t h e 10th p e r c e n t i l e , bone age was delayed a b o u t 2 y e a r s but c l i n i c a l l y she was eutilyroid. Treatment w i t h t,h. r e s u l t e d i n T8H suppresion but s i n g s o f hyperthyroidism appeared. During t h e n e x t 3 y e a r s without any t r e a t m e n t T4, T 3 and bass1 TSH were s t i l l e l e v a t e d and TRH s t i m u l a t e d TSh i n c r e a s e d t o t h e hypothyroid range. A t t h e age o f 9 y e a r s c l i n i c a l symptams of hyperthyroidism were e v i d e n t , Hypothalamo-pituitary s t u d i e s were normal, t h e r e was no evidence f o r n i t u i t a r v tumor. A a r t i s s e l e c t i v e i t u i t a r y r e s i s t a n c e t o t h, was s u E p o s e d ,~i n c e 19SOPthe p a t i e n t~~-%~~~4 i n a dose o f 0.5mdd. Grsdual d e c r e a s e o f TSH l e v e l s was accompanied by r e d u c t i o n i n t h e s i z e of g o i t r e and a m e l i o r a t i o n o f c l i n i c a l symptoms o f hyperthyroidism, confirmed by n o r m a l i s a t i o n of WR, Temporary i n t e r r u pt i o n o f D-T4 t h e r a p y r e s u l t e d i n t h e i n c r e a s e o f a l l c l i n i c a l and biochemical a b a o r m a l i t i e s . To our knowl i d g e t h i s i s t h e f i ? s t case o f h e r t h roidism due t o 1 2 2 D-ri::.
Ocpartments of P e d i a t r i c s . l l n i v e r s i t y H o s p i t a l s . H e s s i n a and Parna ,
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I t a l y . W h i l s t t h e l a s t 10 y e a r s ' l i t e r a t u r e u n a n i n o u s l y p o i n t s o u t t h e i n c r e a s e d p r e v a l e n c e o f s e r u a HCllA i n c h i l d r e n and y o u n g s t e r s u i l h i n s u l i n -d e p e n d e n t d i a l i e t c s n e l l i t u s 
b ) no p a t i e n t has been s h o u i n g g o i t e r o r o l h e r c l i n i c a l s i g n s o f t h y r o i d d y s f u n c l i -
on; c ) no p a t i e n t has b e c n e x h i b i t i n g p c r s i s t c n l o r even t r a n s i e n t changes i n t h y - 
CONTINUOUS SUBCUTANEOUS GLUCAGON INFUSION IS AN EFFECTIVE MEAN OF INCREASING BLOOD GLUCOSE (BG) IN fNPERINSULINEMIC INFANTS.
flyperinsulinemic infants develop severe hypoglycemia due to a major suppression of glucose production by the iiver. Treatnient of this condition is made difficult in a subset of patients by the limited efficacy of drugs, such as diazoxide or corticosteroids. The need for maintaining a large supply of glucose in these patients requires continuous nasogastric feeding and sometinies prolonged peripheral or central venous catheterization. We have used the subcutaneous infusion of glucagon via a small insulin pump in an attempt to maintain BG within normal limits in 5 hypersinulinemic infants previously treated with 15 mg1kg.d diazoxide. Clucagon was infused continuously as a 1 mg/inl 0.5 N saline solution at a rate of 0.37'0.17 mg/kg.dduriiig the 2-12 weeks preceeding subtotal pancreatectomy. No side effects were detected.CG increased from 50228 to 110'57 mgldl (p<0.001), with a consistent effect in all treated children. Less than 6+4% BG values fell below 45 mgldl versus 41t14Z (p<0.025) under previous therapy. Mean insulin values were as expected unchanged (10'7.3 versus 18+13 pU/ml before). During this period, feeding could be discontinued and diminished down to 0.65'0.1 g carbohydrates/kg.h; versus 0.93 '0.1 g1kg.h before. Because of its simplicity and reliability, we propose that the subcutaneous continuous infusion of glucagon should be largely employed for the control of hypoglycemia in infants developing severe hyperinsulinism and/or resistance to diazoxide therapy. SMS 201-995 was used In a 4 month-old boy presenting hypoglycemic seizures with hyperinsulinisrn. The dose of SMS 201-995 was rapidly increased during the first week from 10 ug/kg/day to 100 ug/kg/day, and was administrated using continuous subcutaneous infusion (CS1) durlng 8 months and then 3 or 2 dally subcutaneous infusion per day for 1 month. Capillary blood glucose was measured every 3 hours. Plasma insulln was evaluated twice dally on the first weeks and when blood glucose was lower than 50 mg/dl. Mean blood glucose levels was dramatically and rapidly increased by therapy, frequency of hypoglycemia was strongly reduced, blood glucose/insulin ratio ~ncreased,carbohydrate needs were reduced (0.6g/kg/day). CT Scan of the pancreas performcd before therapy not~ced a global increase ~f the volume of the gland which was no more observed after one month of therapy. Growtti velocity remained In a normal range l'or age. Measure of plasma GH every 20 min durlng 5 hours had shown a normal spontaneous GI! peak of 50 ng/ml. Neurologic development was r~ormal. Others cndocrlrr:'unctlons remalned normal. 'Tolerance of thls treatment was good excepted for translent dlarrllea and vomiting during the flrst 2 weeks of therapy and translent moderate Increase of Gamma GT. Treatment had been interrupted after one and 6 months of therapy with reccurrent hypoglycemia after 3 and 6 days respectively. 3 or 2 subcutaneous injections resulted In a worstly zlycem~c control than CSI therapy.
183 Services de Mddecine Ndonatalc et de MEdecirle Infantile -C l l U de GllENOBLE -BP 217 X -38043 GREN0UI.E CEDEX -FRANCE SOMATOSTATIN TREATMENT OF NEONATAL IIYPERINSULINISM DUE TO FOCAL ADENOMATOSIS OF TllE PANCREAS de report the use of somatostatin in a newborn infant with hyperinsulinism due to focal adenomatosis of thc pancreas. When administred alone at a rate of 2,5 to 7 u/kg/h, the natural somatostatin was documented to be short-(imed able to prevent hypoglycemia. However the association to glucagon infusion at a rate of 2,5 /u/kg/h allowed successful control of patient's hypoglycemia. As hyperinsulinism relapsed a'Tter a subtotal pancreatectomy, a trial with somatostatin analogue SMS 201-995, which has an expected longer duration of action was performed. It lead to a significant rjse in the blood glucose level but failed to prevent safely hypoglycemia even when four injections were performe~l So, three hours after a subcutaneous injection of 10 ug of the analogue, the blood glucose concentration raised sign(ficantly to 5 -7 mmol./l., but after four to five hours, the level dropped again to 1 , 8 -2,2 mmol./l.. The young age of the infant and the cerebral risk of hypoglycemia did not allow us to increase posology and injection's frequency ; then a near total pancreatectomy was performed.
A . Vazeou*, K. Pantsiotou*, M. Kipris*, A.Giannoulia X . Nikalldou*, C. Dacou-Voutetakis First Pediatric Dept., Athens University, Greece.
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HYPERINSULINEMIC HYPOGLYCEMIA (NESIDIOBLASTOSIS?) . OllTCOME OF 7 CASES TREATED WITH LOW LEUCINE DIET AND DIAZOXIDE.
Mental subnormality in hyperinsulinemic hypoglycemia ( R H ) of infancy, in the reported series, ranges from 35 to 60%. We report on the outcome of 7 cases. All but one presented with convulsions prior to the age of 9 months. The diagnosis of HH was based on low glucose-insulin ratlo (G/I) in random blood samples after limited fasting (6.217.1 in HE1 versus 24.7k14.4 in controls), and after leucine ( L ) load (1.7+1 .5 in HH versus 21.2t13.4 in controls) . Random G/I values although lower in infants with HH, as a group, was not diagnostic in individual cases. All subjects were placed on low leucine diet and 6/7 also received diazoxide (10-15mg/kg/day). In all but one child this regimen was effective In raising blood glucose. In one lnfant, partial pancreatectomy was performed with excellent result. One infant has come off Diazoxide and is well and free of hypertrichosis 30 months later. L. tolerance in children retested w h~l e on diazoxide, was normal, while in the chlld on diet alone sensitivity persisted. All infants have normal IQ now. Side effects: liypertrichosis (all), transient rise in alkaline phosphatase (2) and in uric acld (1). In our subjects, random G/I values were indicative but not diagnostic of HH while post L G/I values established the diagnosis. Strict adherence to diet combined with diazoxide gave the best results and llmited the need for pancreatectomy. Either -diet or diazoxide alone proved ineffective.
